Global $6.87 Billion Contrast Agents/Media Market to 2025

DUBLIN, Oct. 15, 2018 /PRNewswire/ --

The "Contrast Agents/Media Global Market - Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The contrast agent global market expected to reach $6,879.0 million by 2025

The increase in diagnostic imaging procedures and interventional imaging procedures, increase in incidence and prevalence of disease conditions, increasing in aging population, expansion in indications of contrast media, growth of medical imaging technologies in emerging market, increasing research activities for contrast agents, and favourable reimbursements are driving the market growth. However, adverse effects related to contrast agents and shortage of radiologists is restraining the market growth. Stringent regulations and availability of alternative products are hampering the market expansion.

The contrast agent global market by molecule is segmented into Iodine based [Ionic (Monomeric and Dimeric), Non-Ionic (Monomeric and Dimeric)], Gadolinium-based contrast agents [Macrocyclic (Ionic and Non-Ionic), Linear (Ionic and Non-Ionic)], microbubble-based contrast agent and others which include Barium, iron and dyes. Iodine-based contrast agent market held the largest market share in 2018 and microbubble segment is growing at high double digit CAGR from 2018 to 2025 due to expansion in disease indications.

Innovations in contrast agents are taking place in the areas of packaging, the development of bulk, multi-dose containers, and polymer containers. For instance, FDA approved Isovue (iopamidol injection) Imaging Bulk Package (IBP) (developed by Bracco) which is a specific combination multi-patient, multi-dose compliant contrast medium for point-of-care use in the computed tomography (CT) suite. Increase in research activities for contrast which is supported by funding from different institutes.

For instance, Ferric Contrast Company received $225,000 for a Phase I Small Business Technology Transfer (STTR) fund in 2017 in for developing iron-based contrast agents for magnetic resonance imaging (MRI) which is an alternative to the Gadolinium complexes that have traditionally been employed in MRI. Likewise, Inlighta Biosciences LLC received a $2 million grant from the National Cancer Institute in 2017 for development of an improved MRI contrast agent, i.e. ProCA32, a next-generation MRI contrast agents that could be utilized for early detection of primary and metastasized liver cancers.

The research is done through collaboration between Inlighta Biosciences, Georgia State University, and Emory University. The funding is used in validation of ProCA32 and used for toxicology a study which is required to support an application to the FDA for human clinical trials.

Key Topics Covered:

1 Executive Summary

2 Introduction
2.1 Key Takeaways
2.2 Report Scope
2.3 Report Description
2.4 Markets Covered
2.5 Stakeholders
2.6 Research Methodology

3 Market Analysis
3.1 Introduction
3.2 Market Segmentation
3.3 Factors Influencing Market
3.3.1 Drivers And Opportunities
3.3.1.1 Increasing Demand For Diagnostic And Interventional Radiology Procedures
3.3.1.2 Increase In Incidence And Prevalence Of Disease Conditions
3.3.1.3 Increase In Aging Population
3.3.1.4 Expansion In Indications Of Contrast Media Market
3.3.1.5 The Growth Of Medical Imaging Technologies In Emerging Markets
3.3.1.6 Increasing Research Activities For Contrast Agents
3.3.1.7 Favorable Reimbursement
3.3.2 Restraints And Threats
3.3.2.1 Side Effect Associated With Contrast Agents.
3.3.2.2 Shortage Of Radiologist.
3.3.2.3 Availability Of Alternative Products
3.3.2.4 Stringent Regulations For Contrast Agents.
3.4 Regulatory Guidelines
3.4.1 United States
3.4.2 Europe
3.4.3 China
3.4.4 Japan
3.4.5 India
3.5 Reimbursement Scenario
3.5.1 Reimbursement Table
3.6 Upcoming Technology
3.7 Clinical Trials
3.8 Patent Trends
3.9 Supply Chain Analysis
3.10 Porter's Five Force Analysis
3.11 Market Share Analysis By Major Players
3.11.1 Contrast Agents Global Market
3.11.2 X-Ray/Ct Contrast Agents Market
3.11.3 MRI Contrast Agents Market
3.11.4 Ultrasound Based Contrast Agents Market
3.12 Contrast Agents Global Consumption

4 Contrast Agents Global Market, By Molecule
4.1 Introduction
4.2 Iodine Based Contrast Media
4.2.1 Iodine Based Ionic Contrast Media
4.2.1.1 Monomers
4.2.1.2 Dimer
4.2.2 Iodine Based Non-Ionic Contrast Media
4.2.2.1 Monomer
4.2.2.2 Dimer
4.3 Gadolinium-Based Contrast Media
4.3.1 Macrocyclic
4.3.1.1 Ionic
4.3.1.2 Non-Ionic
4.3.2 Linear
4.3.2.1 Ionic
4.3.2.2 Non-Ionic
4.4 Microbubble Based Contrast Media
4.5 Other Contrast Media

5 Contrast Agents Global Market, By Modality
5.1 Introduction
5.2 X-Ray/Computed Tomography (CT)
5.3 Magnetic Resonance Imaging (MRI)
5.4 Ultrasound

6 Contrast Agents Global Market, By Application
6.1 Introduction
6.2 Cardiovascular
6.3 Cancer
6.4 Gastrointestinal
6.5 Musculoskeletal
6.6 Neurology
6.7 Nephrology
6.8 Obstetrics And Gynecology
6.9 Urology
6.10 Others

7 Contrast Agents Global Market, By Route Of Administration
7.1 Introduction
7.2 Intravascular
7.3 Oral
7.4 Rectal
7.5 Others

8 Contrast Agents Global Market, By Imaging
8.1 Introduction
8.2 Diagnostic Imaging
8.3 Interventional Imaging

9 Contrast Agents Global Market, By End-Users
9.1 Introduction
9.2 Hospital
9.3 Diagnostic & Ambulatory Surgical Centers
9.4 Other End-User

10 Regional Analysis

11 Competitive Landscape
11.1 Introduction
11.2 Approvals
11.3 Other Key Development
11.4 Collaboration
11.5 Partnership
11.6 Agreement
11.7 New Product Launch

12 Major Player Profiles
12.1 Bayer Group
12.2 Beijing Beilu Pharmaceutical Co., Ltd
12.3 Bracco Group
12.4 Dongkook Life Science
12.5 Fujifilm Holdings Corporation
12.6 Fujipharma Co Ltd
12.7 GE Company (GE Healthcare)
12.8 Guerbet
12.9 Lantheus Medical Imaging Inc.
12.10 Sanochemia Pharmaceutical Ag
12.11 Taejoon Pharm Co., Ltd

Companies Mentioned

• Alzeca Biosciences, Inc.
• Bayer Group
• Beijing Beilu Pharmaceuticals Company Limited
• Biem la San. And Tic, Inc.
• Bracco Group
• Diahan Pharm. Co. Ltd.
• Dongkook Lifescience
• Ferric Contrast Company
• Fujifilm Holding Corporation
• Fujipharma Co. Ltd
• GE Company (GE Healthcare)
• Graton Pharma
• Guerbet, Llc
• Harmony Life Sciences
• IMAX Diagnostic Imaging Limited
• Inlighta Biosciences, LLC
• JB Chemicals And Pharmaceuticals Ltd
• Jodas Expoim Pvt. Ltd
• Lantheus Medical Imaging
• Ligand Pharmaceuticals
• Magnus Health
• Nano-Therapeutics
• Rege Imaging & Cinefilms Private Limited
• Sanochemia Pharmazeutika AG
• Spago Imaging
• Stellence Pharmscience Private Limited
• Taejoon Pharm Co. Ltd.,
• Trivitron Healthcare
• Unijules Life Sciences Ltd
• Unimark Remedies
• Zhejiang Starry Pharma

For more information about this report visit https://www.researchandmarkets.com/research/tsglb6/global_6_87?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets